SCHEMBL3019632

SCHEMBL3019632

O=[C]c1cc(O)cc(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.50
CA12 O43570 5/20 0.39
CA9 Q16790 5/20 0.39
CA2 P00918 4/20 0.39
CA14 Q9ULX7 4/20 0.39
CA1 P00915 4/20 0.39
CA7 P43166 3/20 0.39
CA5A P35218 2/20 0.38
EGFR P00533 2/20 0.37
LCK P06239 1/20 0.36
ACHE P22303 1/20 0.35
FASN P49327 1/20 0.35
CYP3A4 P08684 3/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CA5B Q9Y2D0 1/20 0.33
NQO1 P15559 1/20 0.33
ABL1 P00519 1/20 0.33
ABCB1 P08183 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19024853 0.94 BACE1 (0.41) BACE1CA12CA9CA2CA14
Phloroglucinol SCHEMBL27994526 0.79 BACE1 (0.67) BACE1CA12CA9CA2CA14
SCHEMBL356245 0.75
SCHEMBL3471002 0.73 EGFR (0.31) EGFR
Phloroglucinol SCHEMBL11060846 0.73 BACE1 (0.57) BACE1CA12CA9CA2CA14
SCHEMBL674063 0.73 BACE1 (0.57) BACE1CA12CA9CA2CA14
Phloroglucinol SCHEMBL28193058 0.73 BACE1 (0.57) BACE1CA12CA9CA2CA14
SCHEMBL132438 0.73 KDM4E (0.42) CA12CA9CA2CA14CA1
SCHEMBL910840 0.73
SCHEMBL7291255 0.72 ALDH1A1 (0.42) ACHELMNAALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997007129-A1 SOLUTION SYNTHESIS OF PERIPHERAL ACTING ANALGESIC OPIOID TETRAPEPTIDES BIOCHEM PHARMA INC. (CA) 1997-02-27 WO claimed
CN-109196004-B Engineered scaffold for vascularized tissue repair 加利福尼亚大学董事会 2022-03-18 CN disclosed
US-10918683-B2 Methods to reduce fat accumulation and oxidative damage in liver using green mango extracts and compounds obtained therefrom TCI CO., LTD. (TW) 2021-02-16 US disclosed
CN-110680825-A Mango young fruit extract and application of compound thereof in preparing pharmaceutical composition for reducing fat accumulation or oxidative damage of liver cells 大江生医股份有限公司 2020-01-14 CN disclosed
CN-107236106-B Aromatic hydroxyl-terminated chain extender containing acylhydrazone bond, self-repairing polyurethane and preparation method of chain extender 青岛科技大学 2020-01-07 CN disclosed
CN-109761944-A A kind of chrysin amide derivatives and preparation method thereof and medical usage 武汉翼博济生生物科技有限公司 2019-05-17 CN disclosed
CN-108459000-A Time-resolved fluorescence test strip for detecting fluopyram and application thereof 北方工业大学 2018-08-28 CN disclosed
CN-108367179-A TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS 莱雅公司 2018-08-03 CN disclosed
CN-107329367-A Photosensitive resin composition, method for producing cured relief pattern, semiconductor device, and display device 旭化成株式会社 2017-11-07 CN disclosed
CN-107072898-A Composition in the form of a nanoemulsion or microemulsion or with a layered structure 莱雅公司 2017-08-18 CN disclosed
US-5691341-A ANTILEUKEMIA AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-11-25 US disclosed
US-5681604-A PLANT EXTRACTS; GREEN TEA, TANNIC ACID, EPICATECHIN GALLATE, GALLIC ACID CARBOHYDRATE REACTION PRODUCTS DELAWARE, UNIVERSITY OF 1997-10-28 US disclosed
WO-1997007129-A1 SOLUTION SYNTHESIS OF PERIPHERAL ACTING ANALGESIC OPIOID TETRAPEPTIDES BIOCHEM PHARMA INC. (CA) 1997-02-27 WO disclosed
US-5464833-A Anticarcinogenic agents, antiretrovirus agents or autoimmune diseases OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-11-07 US disclosed
US-5459142-A Autoimmune disease, atherosclerosis, antiischemic agents and nephritis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-10-17 US disclosed
EP-0511879-B1 Pyrazine derivatives OTSUKA PHARMA CO LTD (JP) 1995-03-22 EP disclosed
EP-0623598-A1 APOPTOSIS REGULATOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-11-09 EP disclosed
EP-0511879-A1 Pyrazine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-04 EP disclosed
US-4760064-A Cardiotonic agent OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-07-26 US disclosed
EP-0187322-A1 Carbostyril compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10918683-B2 Methods to reduce fat accumulation and oxidative damage in liver using green mango extracts and compounds obtained therefrom LIPC, GOT2, PNLIP BACE1 1501/4885CA12 4167/4885CA9 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.